Related Experiment Video
Updated: May 29, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study
Andries J Hoitsma1, Ervin S Woodle, Daniel Abramowicz
1Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. a.hoitsma@nier.umcn.nl
Background:
FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine.
Methods:
This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplantation.
Results:
Incidence of treated biopsy-proven acute rejection was 22.9% with FTY720 and 18.5% with MMF. Increased incidence of macular oedema, transient decrease in heart rate and low rate of infections were seen in the FTY720 arm.
Conclusion:
FTY720 combined with tacrolimus and steroids did not show a significant therapeutic advantage over MMF for the prevention of acute rejection in de novo renal transplant recipients.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Kidney Transplant I: Introduction
Continuous Renal Replacement Therapy
Kidney Transplant II: Surgical Procedure
Renal Drug Excretion: Tubular Secretion

